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Introduction
Nitric oxide (NO) is an important effector molecule that is involved 
in many physiological and pathological processes (Bogdan, 2001; 
Ricciardolo et al., 2004). In particular, the rapid generation of NO 
by the inducible NO synthase (iNOS) is a source of potent reactive 
nitrogen species (RNS) that are an important component of host 
defense and play a critical role in the killing of intracellular patho-
gens (Kröncke et al., 1998; Bogdan et al., 2000; Chakravortty and 
Hensel, 2003).
iNOS (or NOS2) is one of three isoforms of the NO syn-
thases, which are responsible for the synthesis of NO and citrul-
line from l-Arg, oxygen, and NADPH (nicotinamide adenine 
dinucleotide phosphate; Knowles and Moncada, 1994; Nathan 
and  Xie,  1994a;  MacMicking  et  al.,  1997b; Alderton  et  al., 
2001). Transcription of iNOS is induced across a wide range   
of cells and tissues by a variety of stimuli such as microbial 
components and cytokines. Its activity is calcium independent, 
in contrast to neuronal NO synthase (nNOS; NOS1) and endo-
thelial NO synthase (eNOS; NOS3), which are constitutively 
expressed and calcium dependent.
A role for iNOS in antimicrobial host defense was first 
demonstrated by deletion of the iNOS gene in mice, which then 
failed to restrain replication of both the bacterium Listeria mono­
cytogenes (MacMicking et al., 1995) and the protozoan parasite 
Leishmania major (Wei et al., 1995; Diefenbach et al., 1998).   
T helper type 1 (Th1) responses, the production of IFN-, IL-12 
and IFN-/, and the subsequent induction of iNOS in macro-
phages are considered important factors in clearance of L. major 
parasites (Diefenbach et al., 1998). iNOS has since been shown to 
be important in other infectious diseases (Kröncke et al., 1998; 
Chakravortty and Hensel, 2003), with iNOS-deficient mice in-
fected with Mycobacterium tuberculosis showing significantly 
higher risk of dissemination and increased mortality (MacMicking 
et al., 1997a; Chan et al., 2001; Chakravortty and Hensel, 2003). 
Consistent with this, administration of an iNOS inhibitor led to 
I
nducible nitric oxide (NO) synthase (iNOS; NOS2) pro-
duces NO and related reactive nitrogen species, which 
are critical effectors of the innate host response and are 
required for the intracellular killing of pathogens such as 
Mycobacterium  tuberculosis  and  Leishmania  major.  We 
have identified SPRY domain–containing SOCS (suppres-
sor of cytokine signaling) box protein 2 (SPSB2) as a novel 
negative regulator that recruits an E3 ubiquitin ligase com-
plex to polyubiquitinate iNOS, resulting in its proteasomal 
degradation. SPSB2 interacts with the N-terminal region of 
iNOS  via  a  binding  interface  on  SPSB2  that  has  been 
mapped by nuclear magnetic resonance spectroscopy and 
mutational analyses. SPSB2-deficient macrophages showed 
prolonged iNOS expression, resulting in a correspond-
ing increase in NO production and enhanced killing of   
L. major parasites. These results lay the foundation for the 
development of small molecule inhibitors that could disrupt 
the SPSB–iNOS interaction and thus prolong the intra-
cellular lifetime of iNOS, which may be beneficial in   
chronic and persistent infections.
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to form an active E3 ubiquitin ligase (Kamura et al., 1998; 
Zhang et al., 2001). The SOCS box is present in >40 proteins 
encompassing at least nine different families that are defined by 
their protein interaction domain. The SPRY domain–containing 
SOCS box protein family (SPSB1–4; also known as SSB-1 to -4) 
is composed of a central SPRY protein interaction domain 
and a C-terminal SOCS box (Hilton et al., 1998; Nicholson and 
Hilton, 1998).
The  SPSB2  SPRY  domain  structure  consists  of  an   
N-terminal helical region packed against a distorted -sandwich 
(Masters et al., 2006; Yao et al., 2006; Kuang et al., 2009). The 
SPRY domains of SPSB1, SPSB2, and SPSB4 but not SPSB3   
interact with prostate apoptosis response protein 4 (Par-4;   
Masters et al., 2006), whereas the SPSB1 Drosophila melanogaster  
homologue, GUSTAVUS, interacts with the DEAD box RNA   
helicase VASA (Styhler et al., 2002). Short, contiguous sequences 
were identified recently in Drosophila VASA (DINNNN) and   
human Par-4 (ELNNNL) that interact with an extended interface 
on the SPSB SPRY domain formed by five variable loops (Woo 
et al., 2006). The presence of a similar motif in VASA and Par-4 
implies a common mechanism for binding partner recognition by 
this subclass of SPRY domains.
Although iNOS had been shown to be ubiquitinated and 
degraded in cell lines (Musial and Eissa, 2001; Kolodziejski   
et al., 2002, 2004), the responsible E3 ubiquitin ligases were un-
known. In this study, we demonstrate that SPSB2 interacts with 
an NNN-containing motif in the N-terminal region of iNOS. We 
also show that SPSB2 is the adaptor protein in the E3 ubiquitin 
ligase complex that ubiquitinates iNOS, targeting it for pro-
teosomal degradation and thereby regulating NO production and 
macrophage killing of L. major, the intracellular parasite respon-
sible for human cutaneous leishmaniasis.
Results
Identification of iNOS as a potential SPSB 
binding partner
The  short  sequences  DINNNN  in  Drosophila  VASA  and 
ELNNNL in human Par-4 have been shown to mediate their   
interaction with the SPRY domains of GUSTAVUS and SPSB1 
and SPSB2, respectively (Woo et al., 2006). However, this motif 
is not present in mouse or human VASA or in mouse Par-4.   
the reactivation of tuberculosis in mice (Flynn et al., 1998).   
A recent study has shown that a polymorphism in the NOS2A 
(iNOS) gene influences susceptibility to tuberculosis, suggesting 
a role for iNOS in the pathogenesis of human disease (Gómez   
et al., 2007). In support of this, alveolar macrophages from pa-
tients infected with M. tuberculosis express iNOS, and these   
cells lose their antimycobacterial activity when treated with iNOS 
inhibitors (Nicholson et al., 1996).
Over the past decade, many additional roles have been rec-
ognized for iNOS in the immune system. TNF/iNOS-producing 
dendritic cells not only mediate innate immune defense against 
L. monocytogenes infection in mice (Serbina et al., 2003) but 
also regulate IgA production in mucosa-associated lymphoid tis-
sues, with impairment of IgA class switching in iNOS-deficient 
mice (Tezuka et al., 2007). Production of NO by iNOS in re-
sponse to infection can kill invasive microbes on one hand, but 
cause NO-mediated cytotoxicity and tissue damage on the other 
(Kröncke et al., 1998; Bogdan, 2001). In some situations, the   
expression of iNOS is associated with inflammation and more 
severe disease outcomes (Bogdan, 2001). Excessive NO produc-
tion triggers fatal cardiovascular collapse during septic shock, 
but  the  degree  of  protection  from  sepsis-related  mortality  in 
iNOS-deficient mice varies considerably according to the genetic 
background (Laubach et al., 1995; MacMicking et al., 1995; 
Wei et al., 1995).
The production of NO needs to be tightly regulated, and, 
as such, iNOS expression and activity are controlled at multiple 
levels, including transcriptional, translational, and posttransla-
tional regulation (Knowles and Moncada, 1994; Nathan and 
Xie, 1994b; MacMicking et al., 1997b; Alderton et al., 2001).   
In particular, iNOS is regulated by ubiquitination and proteasomal 
degradation and has a relatively short half-life in primary bron-
chial epithelial cells and several cell lines (Musial and Eissa, 
2001; Kolodziejski et al., 2002, 2004). Protein ubiquitination 
involves the sequential transfer of a ubiquitin molecule via an 
E1-E2-E3 enzyme cascade (Hershko and Ciechanover, 1998), 
the final step of which requires an E3 ligase that functions both 
as a substrate recognition module and a catalyst for the transfer 
of ubiquitin to a Lys in the substrate protein (Petroski and   
Deshaies, 2005). The SOCS (suppressor of cytokine signaling) 
box is a 40-residue domain, first identified in the SOCS proteins 
that, in the presence of elongin BC, recruits Cullin5 and Rbx2 
Figure 1.  Domain structure of NO synthases and 
amino acid sequence alignments of the N-terminal   
region of iNOS proteins.  The  EKDINNNVXK  se-
quence is conserved in iNOS (NOS2) but is not 
present in either eNOS (NOS3) or nNOS (NOS1). 
The sequence of the mouse iNOS N-terminal pep-
tide used in ITC and NMR experiments (iNOS19–31) 
is indicated. The amino acid numbering refers to 
the mouse protein (Swiss-Prot ID P29477). Outlining   
indicates regions of conserved amino acid sequence. 
Red lettering indicates amino acid similarity, and 
red shading indicates amino acid identity.131 SPSB2 targets iNOS for proteasomal degradation • Kuang et al.
Ala substitutions of these residues produced two- to fourfold 
lower SPSB2 binding affinities compared with wild-type pep-
tide. Indeed, when these three residues were mutated to Ala   
simultaneously, SPSB2 binding affinity was decreased by 24-
fold, suggesting that the SPSB binding sequence in iNOS is 
more extensive than that reported for the GUSTAVUS–VASA or 
SPSB–Par-4 interactions. Binding of an SPSB2 SPRY domain in 
which Tyr120 had been mutated to Ala was assessed by ITC; the 
iNOS peptide bound Y120A-SPSB2 (12–224) with 5,000-fold 
reduced affinity, indicating that Tyr120 in SPSB2 is critical for 
binding to the iNOS peptide, as it is for SPSB2 binding to Par-4 
(Masters et al., 2006).
Nuclear  magnetic  resonance  (NMR)  spectroscopy  was 
used  to  further  characterize  the  SPSB2–iNOS  peptide  inter-
action. Titration of the unlabeled iNOS N-terminal peptide into 
a 
15N-labeled SPSB2 (12–224) sample caused a gradual disap-
pearance of the free subset of SPSB2 cross-peaks and the simul-
taneous appearance of a bound subset of cross-peaks in the 
1H-
15N heteronuclear single quantum coherence (HSQC) spec-
tra (Fig. 2 A). The residues that exhibited chemical shift pertur-
bations were found on a continuous surface on SPSB2 in the 
vicinity of Tyr120, Val206, and Trp207, forming an iNOS peptide–
binding site (Fig. 2 B).
SPSB1, SPSB2, and SPSB4 interact with 
full-length iNOS
iNOS  protein  was  induced  in  bone  marrow–derived  macro-
phages (BMDMs) by treatment with lipopolysaccharide (LPS) 
and IFN-. Cells were lysed, and iNOS-expressing lysates were 
incubated with SPSB2 (12–224) protein coupled to Sepharose 
beads. SPSB2-associated proteins were then separated by SDS-
PAGE, and iNOS was detected by Western blotting with spe-
cific  antibodies.  Full-length  iNOS  protein  bound  to  SPSB2 
(12–224),  but Y120A-SPSB2  (12–224)  pulled  down  only  a 
minimal amount of iNOS, confirming that Tyr120 is critical for 
the interaction (Fig. 2 C). These results are consistent with our 
ITC data and indicate that the iNOS peptide–binding site on the 
SPSB2 SPRY domain identified by NMR is involved in binding 
full-length iNOS protein.
To investigate whether other SPSB family members were 
able to interact with iNOS, 293T cells were transiently trans-
fected  with  cDNA  expressing  SPSB1,  SPSB2,  SPSB3,  or 
SPSB4 with N-terminal Flag epitope tags. The 293T cells were 
lysed and mixed with iNOS-expressing lysates derived from 
BMDMs. SPSB proteins were then immunoprecipitated using 
anti-Flag antibodies coupled to Sepharose, and association with 
iNOS was analyzed by Western blotting. SPSB2 and SPSB4 but 
not SPSB3 were able to coprecipitate iNOS protein. In compar-
ison with SPSB2 and SPSB4, SPSB1 bound iNOS relatively 
weakly, taking into account that slightly less SPSB1 protein was 
expressed, as detected by an anti-Flag blot of cell lysates. This 
implies that, although SPSB1, SPSB2, and SPSB4 were able to 
interact with iNOS, binding affinity may differ among these 
family members (Fig. 2 D).
To  determine  whether  iNOS  and  SPSB2  formed  an   
endogenous  complex,  C57BL/6  BMDMs  were  stimulated 
with  LPS/IFN-  and  then  lysed,  and  SPSB2  proteins  were   
This lack of conservation across species suggests that neither 
Par-4 nor VASA is a key physiological target of the mammalian 
SPSB proteins. Therefore, we sought other candidate targets for 
SPSB proteins.
A sequence analysis using ScanProsite (de Castro et al., 
2006) identified 11 mouse and 16 human proteins that contained 
the [DE]-[IL]-N-N-N sequence. One of these candidates was the 
inducible form of NO synthase (iNOS). The DINNN sequence 
(residues 23–27) is located in the N-terminal region of mouse 
iNOS, before the first structured domain (the oxygenase do-
main). This motif and certain flanking residues are conserved in 
iNOS sequences from different species, including human, mouse, 
bovine, chicken, and goldfish, but nNOS and eNOS do not   
contain this motif (Fig. 1). The N-terminal region of iNOS is 
predicted to be intrinsically disordered using the programs Fold-
Index (Prilusky et al., 2005) and IUPred (Dosztányi et al., 2005; 
unpublished data), further suggesting that this region could be 
accessible for SPSB binding.
The SPSB2 SPRY domain interacts with 
the iNOS N-terminal sequence
A series of wild-type and mutant peptides corresponding to res-
idues 19–31 of murine iNOS were synthesized, and their bind-
ing affinities for the SPSB2 SPRY domain (residues 12–224) 
were measured using isothermal titration calorimetry (ITC; Fig. S1 
and Table I). The wild-type iNOS peptide bound SPSB2 with 
high affinity (Kd 13 nM). Mutation of Asp23, Asn25, and Asn27 
to Ala dramatically reduced the binding affinity, indicating that 
these  residues  make  a  major  contribution  to  binding,  which   
is  consistent  with  the  structural  requirements  previously  re-
ported  for  the  GUSTAVUS–VASA  interaction  (Woo  et  al., 
2006). Additional conserved residues flanking the DINNN se-
quence (Lys22, Val28, and Lys30) also contribute to binding, as 
Table I.  ITC analysis of interactions between the SPSB2 SPRY do-
main and wild-type or mutant iNOS N-terminal peptides
Peptide Sequence Kd
nM
A Ac-KEEKDINNNVKKT-NH2 13.3 ± 3.0
B Ac-KEAKDINNNVKKT-NH2 14.0 ± 3.0
C Ac-KEEADINNNVKKT-NH2 127 ± 23
D Ac-KEAADINNNVKKT-NH2 65.4 ± 7.4
E Ac-KEEKAINNNVKKT-NH2 21,600 ± 750
F Ac-KEEKDANNNVKKT-NH2 23.5 ± 9.9
G Ac-KEEKDIANNVKKT-NH2 17,200 ± 7,400
H Ac-KEEKDIQNNVKKT-NH2 40,500 ± 7,200
I Ac-KEEKDINANVKKT-NH2 826 ± 20
J Ac-KEEKDINNAVKKT-NH2 ND
a
K Ac-KEEKDINNQVKKT-NH2 ND
a
L Ac-KEEKDINNNAKKT-NH2 56.8 ± 11.2
M Ac-KEEKDINNNVKAT-NH2 29.8 ± 12.2
N Ac-KEEKDINNNAKAT-NH2 180 ± 39
O Ac-KEEADINNNAKAT-NH2 311 ± 37
Typical ITC raw data and titration curves are shown in Fig. S1. Bold letters 
indicate the amino acid substitution. The Kd column shows dissociation constants 
with errors from the Origin-calculated association constants transferred as the 
same fractions of primary values.
aBinding affinity was too low to be determined under these conditions.JCB • VOLUME 190 • NUMBER 1 • 2010   132
Figure 2.  SPSB2 interacts with full-length iNOS protein, and Tyr120 in the SPSB2 SPRY domain is critical for binding. (A) Overlay of the 
1H-
15N HSQC 
spectra of 0.1 mM 
15N-labeled SPSB2 (12–224) in the absence (orange) and presence (green) of unlabeled iNOS peptide at SPSB2/iNOS peptide   
molar ratios of 1:1.5. Samples were in 95% H2O/5% 
2H2O containing 10 mM Na phosphate, 50 mM Na chloride, 2 mM EDTA, 2 mM DTT, and 0.02% 
(wt/vol) Na azide at pH 7.0. Spectra were recorded at 500 MHz and 22°C. (B) Ribbon model of SPSB2 (12224; PDB ID number 3EK9; Kuang et al., 
2009) with residues whose 
1H-
15N cross-peaks experienced chemical shift perturbations upon iNOS peptide binding shown in pink. Helices, strands, and 
loops are colored green, gold, and purple, respectively. (C) BMDMs from C57BL/6 mice were incubated with 20 ng/ml IFN- and 1 µg/ml LPS overnight, 
lysed, and incubated with NHS-Sepharose beads coupled with recombinant SPSB2 or Y120A-SPSB2 protein or with uncoupled NHS-Sepharose beads 
(Bead) for 3 h at 4°C. Associated iNOS protein was detected by Western blotting (top). Equivalent amounts of SPSB2 and Y120A-SPSB2 were confirmed 
by reprobing with anti-SPSB2 antibodies (bottom). (D) 293T cells were transiently transfected with vector alone or cDNA encoding Flag-tagged SPSB1, 
SPSB2, SPSB3, or SPSB4. Cells were lysed and mixed with BMDM lysates from cells induced to express iNOS. Flag-tagged proteins were immunoprecipi-
tated using anti-Flag antibodies, and coimmunoprecipitation of iNOS was detected by Western blotting (top). Membranes were stripped and reprobed 
with rat anti-Flag antibodies (middle). Comparative expression of Flag-tagged proteins in 293T lysates is shown in the bottom panel. (E) BMDMs from 
either wild-type (Spsb2
+/+) or SPSB2-deficient mice (Spsb2
/) were incubated with (+) or without () 20 ng/ml IFN- and 1 µg/ml LPS overnight and 
lysed, and endogenous SPSB2 proteins were immunoprecipitated using rabbit anti-SPSB2 antibody coupled to NHS-Sepharose. Associated iNOS protein 
was detected by Western blotting (top). Membranes were stripped and reprobed using biotinylated anti-SPSB2 antibody (middle). iNOS induction was 
confirmed by Western blotting of protein lysates (bottom). (F) 293T cells were transiently transfected with cDNA encoding Flag-tagged wild-type or mutant 
SPSB2 in which residues in the SPSB2 SPRY domain were mutated to Ala (and for Tyr120, also to Phe). Cells were lysed and mixed with BMDM lysates 
from cells induced to express iNOS. Flag-tagged proteins were immunoprecipitated using anti-Flag antibodies, and associated iNOS was detected by 
Western blotting. IP, immunoprecipitation.133 SPSB2 targets iNOS for proteasomal degradation • Kuang et al.
SPSB2  appeared  the  most  likely  candidate  as  the  key 
physiological regulator of iNOS in macrophages, particularly as 
SPSB1 and SPSB4 did not appear to be expressed in BMDMs 
(Masters et al., 2005). Therefore, our subsequent experiments 
have focused on this member of the SPSB family.
SPSB2 regulates the proteasomal 
degradation of iNOS
To determine whether the kinetics or magnitude of iNOS ex-
pression were altered in the absence of SPSB2, BMDMs from 
SPSB2-deficient mice (Spsb2
/) or wild-type littermates were 
stimulated with LPS/IFN- for various times and then lysed, 
and iNOS expression was detected by Western blot. Although 
the initial kinetics of iNOS induction appeared to be the same   
in both wild-type and Spsb2
/ BMDMs, there was a modest 
increase in iNOS protein in Spsb2
/ BMDMs after 4-, 6-, and   
8-h stimulation (Fig. 3 A). A greater difference in iNOS expres-
sion  between  wild-type  and  Spsb2
/  BMDMs  was  evident   
after the stimulus was removed and iNOS had begun to be   
degraded (Fig. 3 B). Indeed, clearance of iNOS in wild-type 
BMDMs was essentially complete at 24 h after wash, whereas 
iNOS was still visible after 32 h in Spsb2
/ BMDMs. This en-
hanced expression of iNOS was also observed when LPS was 
used alone (Fig. S3). The results indicate that the initial kinetics 
of iNOS induction are unaltered in Spsb2
/ BMDMs but the clear-
ance of iNOS protein by the degradation machinery is impaired.   
immunoprecipitated  and  analyzed  by  Western  blotting  with 
anti-iNOS antibodies. iNOS coimmunoprecipitated with SPSB2 
from wild-type but not SPSB2-deficient macrophages (Spsb2
/; 
Fig. 2 E), indicating that iNOS was likely to be a genuine physio-
logical target of SPSB regulation. Less SPSB2 protein was   
immunoprecipitated in LPS/IFN-–activated BMDMs compared 
with unstimulated controls, with a faster-migrating nonspecific 
band evident in Spsb2
/ lanes. Probing of lysates using spe-
cific antibody confirmed iNOS expression in cells derived from 
both wild-type and Spsb2
/ mice (Fig. 2 E). The apparent down-
regulation of SPSB2 protein occurred at the mRNA level, with 
a 10-fold reduction in SPSB2 mRNA levels after 4-h treatment 
with LPS/IFN- (Fig. S2).
To further interrogate the SPSB2–iNOS binding interface, 
293T cells were transiently transfected with cDNA expressing 
either SPSB2 or various SPSB2 mutants (Masters et al., 2006; 
Kuang et al., 2009), and interaction with iNOS was assessed 
by anti-Flag immunoprecipitation and Western blotting for 
iNOS association. Mutation of Arg100/Gly101, Tyr120, Leu123/
Leu124/Leu125, or Val206 to Ala or mutation of Tyr120 to Phe 
greatly abrogated SPSB2 interaction with iNOS. Mutation of 
Thr102/His103, Ser126/Asn127/Ser128, or Trp207 to Ala dra-
matically reduced SPSB2 interaction with iNOS, whereas mu-
tation of either Asp118/His119 or Gln160/Leu161 had no effect. 
Reblot of the anti-Flag immunoprecipitates confirmed expres-
sion of all of the SPSB2 mutants (Fig. 2 F).
Figure  3.  iNOS clearance is reduced after stimulus in 
SPSB2-deficient  macrophages.  (A  and  B)  BMDMs  from 
either wild-type littermates (Spsb2
+/+) or SPSB2-deficient 
mice (Spsb2
/) were incubated with IFN- and LPS for 
the times indicated (A) or incubated with or without () 
IFN- and LPS overnight, washed, replenished with fresh 
medium, and lysed at the indicated times after wash (B). 
Lysates were then separated by SDS-PAGE and analyzed 
by  Western  blotting  using  anti-iNOS  antibody  (top). 
Equivalent  protein  loading  was  confirmed  by  stripping 
and  reprobing  membranes  with  antitubulin  antibody 
(anti-Tub;  bottom).  (C)  Thioglycollate-elicited  peritoneal 
macrophages from Spsb2
/ and littermate control mice 
(Spsb2
+/+) were cultured overnight in medium containing 
LPS/IFN-, washed, replenished with fresh medium, and 
lysed at the indicated times after wash. iNOS expression 
was detected by Western blotting (top). Equivalent protein 
loading was confirmed by stripping and reprobing mem-
branes with antitubulin antibody (bottom).JCB • VOLUME 190 • NUMBER 1 • 2010   134
iNOS. BMDMs were generated from mice expressing a Flag-
tagged Spsb2 transgene under a constitutive promoter (Spsb2
T/+) 
and from wild-type littermates. LPS/IFN-–stimulated iNOS 
expression was reduced in Spsb2
T/+ BMDMs after overnight 
stimulation  (time  0)  and  rapidly  decreased  after  wash  in 
comparison with wild-type controls (Fig. 4 A), indicating that 
iNOS degradation was enhanced in these macrophages. iNOS 
SPSB2 regulation of iNOS expression was confirmed in perito-
neal macrophages elicited by thioglycollate injection, with 
iNOS expression after wash significantly prolonged in Spsb2
/ 
cells (Fig. 3 C).
As genetic deletion of SPSB2 appeared to result in an   
elevation of iNOS levels, we investigated whether artificially 
increasing SPSB2 levels could correspondingly down-regulate 
Figure  4.  Expression  of  an  SPSB2  transgene  en-
hances iNOS degradation; this requires the SOCS box 
and is proteasome dependent. (A, B, and C) BMDMs 
from littermate controls (Spsb2
+/+), SPSB2 transgenic 
mice  (Spsb2
T/+),  or  SPSB2  transgenic  mice  lacking 
the  SOCS  box  (Spsb2SB
T/+)  were  incubated  with 
or without () LPS/IFN- overnight, washed, replen-
ished with fresh medium with (+) or without () 10 µM   
of the proteasomal inhibitor MG-132, and lysed at 
the  indicated  times  after  wash.  Proteins  were  then 
analyzed by Western blotting using anti-iNOS anti-
body (top). Equivalent protein loading was confirmed 
by  stripping  and  reprobing  membranes  with  anti-
tubulin antibody (anti-Tub; bottom). (D) Expression of 
Flag-tagged SPSB2 transgenes in LPS/IFN-–treated 
BMDMs from Spsb2
T/+ and Spsb2SB
T/+ mice was 
confirmed by anti-Flag immunoprecipitation (IP) and 
Western blotting (top). Membranes were stripped and 
reprobed for iNOS association (upper middle). iNOS 
expression was confirmed by Western blotting of cell 
lysates (lower middle) and equivalent protein levels by 
Western blotting with antitubulin antibody (bottom).135 SPSB2 targets iNOS for proteasomal degradation • Kuang et al.
16 h after infection. Spsb2
/ BMDMs produced slightly more 
NO2
 than wild-type macrophages, whereas NO2
 generation by 
Spsb2
T/+ BMDMs was comparable with wild-type in the absence 
of IFN- and reduced in the presence of IFN- (Fig. 6 C). Com-
pared with that induced by LPS, the difference in NO production 
between  Spsb2
/  and  wild-type  macrophages  appeared  to  be 
modest in response to L. monocytogenes infection. In comparison, 
Spsb2
/ BMDMs infected with Mycobacterium bovis (Bacillus 
Calmette-Guérin  [BCG])  produced  more  NO2
  than  wild-type 
BMDMs 24 and 48 h after infection; NO2
 production was aug-
mented in the presence of IFN-, and by 48 h, the amounts were 
similar between wild-type and Spsb2
/ cells (Fig. 6 D).
L. major killing is enhanced in Spsb2
/ 
macrophages
iNOS has previously been shown to be critical for the clearance of 
L. major parasites in mouse models of disease, with iNOS knock-
out mice being highly susceptible to infection (Wei et al., 1995; 
Diefenbach et al., 1998). This led us to investigate whether the   
observed changes in iNOS and NO production were sufficient to 
result in enhanced macrophage killing of L. major parasites.   
BMDMs from Spsb2
+/+, Spsb2
/, or Spsb2
T/+ mice were infected 
with L. major parasites in the presence or absence of IFN-, and 
the culture supernatants were assayed for NO2
. In the absence of 
cytokine, secreted NO2
 was almost undetectable. However, NO2
 
was readily detected in infected cultures containing IFN-, with 
SPSB2-deficient  macrophages  producing  slightly  more  NO2
 
than wild-type macrophages (Fig. 7 A). The ability of the   
degradation was not enhanced in BMDMs from mice express-
ing the Spsb2 transgene lacking the SOCS box (Spsb2SB
T/+), 
showing that the SPSB2 regulation of iNOS is SOCS box de-
pendent (Fig. 4 B). Moreover, regulation of iNOS protein by 
SPSB2  was  dependent  on  the  proteasome,  as  the  enhanced 
iNOS degradation was abrogated in Spsb2
T/+ BMDMs treated 
with the proteasomal inhibitor MG-132 (Fig. 4 C). Macrophage 
expression of the SPSB2 transgenes was confirmed by anti-Flag 
immunoprecipitation and Western blotting (Fig. 4 D, top). Reblot 
of the anti-Flag immunoprecipitates with anti-iNOS antibody 
showed coimmunoprecipitation of iNOS with both full-length 
and SOCS box–deleted forms of SPSB2 (Fig. 4 D, upper middle).
SPSB2 induces iNOS ubiquitination in vitro
SOCS box proteins recruit an E3 ubiquitin ligase complex that, 
in the presence of E1 and E2 enzymes, polyubiquitinates inter-
acting proteins, targeting them for proteasomal degradation.   
A cell-free ubiquitination assay was established to demonstrate 
SPSB2-dependent ubiquitination of iNOS. LPS/IFN-–stimulated 
macrophage lysates from Spsb2
/ mice were used as a source   
of iNOS and incubated with ubiquitin and a trimeric SPSB2/
elongin BC complex in the presence of E1 and E2 (UbcH5a) en-
zymes, Rbx2, and Cullin5 for various times. The reaction mixtures 
were then analyzed by SDS-PAGE and Western blotting with anti-
iNOS antibodies. Enhanced polyubiquitination of iNOS, as indi-
cated by high molecular weight laddering, was observed after 
10- and 40-min incubation in the presence of the SPSB2/elongin 
BC complex (Fig. 5 A and Fig. S4). This was completely inhibited by 
the addition of free iNOS peptide (Ac-KEEKDINNNVKKT-NH2). 
Coomassie blue staining was used to demonstrate equal input of 
the E1, E2, and E3 components (Fig. S3).
To confirm that the free peptide was indeed competing 
with full-length iNOS for interaction with SPSB2, 293T cells 
were transiently transfected with cDNA expressing Flag-tagged 
SPSB2, lysed, and mixed with iNOS-expressing macrophage 
lysates containing increasing amounts of free iNOS peptide. 
The SPSB2 interaction with iNOS was modestly inhibited by 
100 nM of iNOS peptide and completely inhibited by 1 µM of 
peptide (Fig. 5 B).
SPSB2 regulation of iNOS results in 
altered NO output
BMDMs from C57BL/6, Spsb2
/, Spsb2
T/+, or Spsb2SB
T/+ mice 
were stimulated with 2 and 20 ng/ml LPS for 24 h, and the culture 
supernatant was assayed for NO2
 (a stable breakdown product   
of NO) production using the Griess reaction. In both instances, 
Spsb2
/ BMDMs produced significantly more NO2
 compared 
with wild-type macrophages, whereas NO2
 generation by Spsb2
T/+ 
BMDMs was reduced (Fig. 6 A). Peritoneal macrophages from 
Spsb2
/ mice also produced significantly more NO2
 than macro-
phages from wild-type controls (Fig. 6 B). To determine whether 
SPSB2 regulates NO production in response to live bacilli,   
BMDMs from C57BL/6, Spsb2
/, Spsb2
T/+, and Spsb2SB
T/+ 
mice were preincubated with or without IFN-, washed, and in-
fected with L. monocytogenes. Cells were then washed and cul-
tured in DME containing 10 µg/ml gentamicin, a membrane- 
impermeant antibiotic, and NO2
 production was measured   
Figure  5.  SPSB2 induces iNOS ubiquitination in vitro.  (A)  An  in  vitro 
ubiquitination assay was performed using recombinant E1, E2, and E3 
ligase components and macrophage lysates as a source of iNOS. Excess 
free iNOS peptide was added as indicated. The reaction mixture was 
then  separated  by  SDS-PAGE  and  analyzed  by  Western  blotting  with 
anti-iNOS antibody. Coomassie blue stain of the gel is shown in Fig. S2.   
(B) 293T cells were transiently transfected with cDNA expressing Flag-
tagged  SPSB2,  lysed,  and  mixed  with  iNOS-expressing  macrophage 
lysates  containing  increasing  amounts  of  free  iNOS  peptide.  Anti-Flag   
immunoprecipitates were then assessed for iNOS interaction by SDS-PAGE 
and Western blotting with anti-iNOS antibody. IP, immunoprecipitation.JCB • VOLUME 190 • NUMBER 1 • 2010   136
regulated. In this study, we have identified SPSB2 as the E3 
ubiquitin ligase adaptor protein responsible for regulating 
iNOS protein levels. In response to endotoxin and various 
infectious  agents,  iNOS  and  NO  are  enhanced  in  macro-
phages from SPSB2-deficient mice, and this change in NO 
production  is  sufficient  to  enhance  macrophage  killing  of   
L. major parasites in vitro. iNOS and NO are correspondingly 
decreased in macrophages engineered to express SPSB2 under 
a constitutive promoter.
SPSB proteins, like other SOCS box–containing proteins, 
are predicted to regulate the expression of interacting protein 
partners through a SOCS box–associated E3 ubiquitin ligase 
complex, which ubiquitinates the substrate protein, targeting it 
for proteasomal degradation. Before our identification of iNOS, 
the physiological target for SPSB2 was unknown. Several SPSB-
binding proteins such as Par-4, VASA, and c-Met have been 
identified (Styhler et al., 2002; Wang et al., 2005; Masters et al., 
2006), and it seems likely that, at least for Par-4 and VASA, the 
underlying molecular basis for interaction with the SPRY do-
main is the presence of a D/E-I/L-NNN peptide motif (Woo   
et al., 2006). We have shown that the interaction with iNOS is 
mediated by a core DINNN sequence, although our NMR and 
ITC  data  suggest  that  the  SPSB2  SPRY–peptide  interface  is 
more extensive than that described for either VASA or Par-4, 
with additional flanking residues in iNOS such as Lys22, Val28, 
and Lys30 making a substantial contribution to the interaction. 
Indeed, the affinity of SPSB2 for the iNOS peptide (Kd 13 nM) 
is higher than that reported for either SPSB1 or SPSB2 binding 
to Par-4 (Kd 146 nM and 4.7 µM, respectively; Woo et al., 2006). 
The high affinity of the peptide interaction and the ability of the 
synthetic iNOS peptide to competitively inhibit binding to full-
length iNOS strongly imply that this motif is the critical inter-
action site.
macrophages to kill L. major parasites was then assessed. The ini-
tial infection rates were comparable at 5 h after infection, but by 
48 h after infection, macrophages from Spsb2
/ mice showed 
significantly enhanced killing of L. major parasites when com-
pared with macrophages derived from Spsb2
+/+ control mice   
(Fig. 7, B and C). The mean number of parasites per infected cell 
did not differ between the two genotypes (unpublished data). To 
confirm that the observed differences were indeed caused by en-
hanced iNOS expression, the experiment was repeated with the 
inclusion of a specific iNOS inhibitor after infection (1400W; 
Garvey et al., 1997). Initial 5-h infection rates were again compa-
rable (18.6 ± 1.7% for Spsb2
+/+ and 19.1 ± 2.5% for Spsb2
/), 
and the addition of the iNOS inhibitor reversed the enhanced   
killing seen in Spsb2
/ macrophages (Fig. 7 C). Thus, the modest 
elevation in NO production by SPSB2-deficient macrophages cor-
relates with increased parasite killing in vitro. However, both the 
low level of NO production (Fig. 7 A) and the modest increase in 
parasite survival in the presence of the iNOS inhibitor (Fig. 7 C) 
suggest that the main mechanism by which macrophages control 
L. major replication is likely to be independent of iNOS. Coupled 
with the enhanced parasite survival in iNOS-deficient mice (Wei 
et al., 1995) and recent studies that demonstrate an important role 
for iNOS-producing dendritic cells (Serbina et al., 2003; Copin   
et al., 2007; De Trez et al., 2009), our data would suggest that cell 
types other than macrophages are important for the clearance of   
L. major parasites in mouse models of infection.
Discussion
The rapid production of NO by iNOS constitutes a critical 
frontline response to microbial infection. Given the potential 
harm caused by excessive NO production, it is paramount 
that the initiation and extent of iNOS expression are tightly 
Figure 6.  SPSB2-deficient macrophages show   
elevated NO production. (A and B) BMDMs 
from  C57BL/6,  Spsb2
/,  Spsb2
T/+,  and 
Spsb2SB
T/+ mice (A) and peritoneal macro-
phages  from  Spsb2
+/+  and  Spsb2
/  mice 
(B) were cultured for 24 h in medium contain-
ing  either  2  or  20  ng/ml  LPS.  (C)  BMDMs 
from  C57BL/6,  Spsb2
/,  Spsb2
T/+,  and 
Spsb2SB
T/+  mice  were  preincubated  with 
or without 20 ng/ml IFN-, washed with PBS, 
and infected with L. monocytogenes in DME 
without  antibiotics  for  30  min.  Cells  were 
then washed and cultured in DME containing   
10 µg/ml gentamicin for 16 h. (A, B, and C) 
Data are shown as mean ± SD (n ≥ 3, where 
each  replicate  represents  cells  derived  from 
individual mice). (D) BMDMs from Spsb2
+/+, 
Spsb2
/, and Spsb2
T/+ mice were stimulated 
overnight with (+) or without () IFN- and then 
infected with M. bovis BCG for 2 h, extracel-
lular bacteria were removed, and supernatants 
were assayed for NO production 24 and 48 h   
after infection. The pound signs (#) indicate 
that nitrite is below detectable levels. Data are 
shown as mean ± SD of quadruplicate cultures 
from one of two experiments. *, P < 0.05.137 SPSB2 targets iNOS for proteasomal degradation • Kuang et al.
with wild-type controls (not depicted). In this instance, either 
the levels of NO may not reach a level that is detrimental to   
mycobacterial survival or the mycobacteria may be able to adopt 
protective mechanisms to overcome the elevated levels of NO. 
The in vitro infection of macrophages does not always reflect 
disease progression in mouse models of infection (unpublished 
data), and future work will address the in vivo consequences in 
mice lacking SPSB2.
Interestingly, SPSB2 mRNA and protein were transiently 
down-regulated after LPS/IFN- treatment, the lowest level of 
SPSB2 mRNA corresponding to the initial induction of iNOS 
protein, as detected by Western blotting (Fig. 2 E and Fig. S2). 
This suggests another level of cellular control and could poten-
tially provide an alternative physiological mechanism for the 
stimulation of iNOS activity. However, activation of Toll-like 
receptor  pathways  will  induce  multiple  downstream  effects   
(including down-regulation of SPSB2), whereas targeting the 
SPSB2–iNOS  interaction  would  specifically  enhance  iNOS 
protein expression. The production of NO and related RNS are 
central to the killing of many microbial pathogens, not just the 
few examined in this study. SPSB2 clearly has a nonredundant 
role in macrophages and may, in general, function as a cellular 
sensor to negatively regulate NO production and limit toxicity 
once the initial infection has been resolved and the flood of   
cytokines ceases (Fig. 8). Interestingly, SPSB1 and SPSB4 are 
also able to bind iNOS when overexpressed, and it remains pos-
sible that all three proteins act in concert to regulate the magni-
tude and extent of iNOS expression in different disease/cellular 
contexts. Future studies will be directed at clarifying whether 
other SPSB proteins also have a role in regulating iNOS.
The role of iNOS is not limited to fighting infectious dis-
eases, with iNOS and NO implicated in a diverse range of pa-
thologies such as inflammation and autoimmunity (Kröncke et al., 
1998; Bogdan, 2001), Alzheimer’s disease (Nathan et al., 2005; 
Colton et al., 2006), asthma (Xiong et al., 2000; Prado et al., 
2006),  diabetes  (Cnop  et  al.,  2005),  and  cancer  (Fukumura   
et al., 2006). Understanding the structural basis for the SPSB–
iNOS interaction lays the foundation for the development of 
Many SOCS box–containing E3 ubiquitin ligases such as 
SOCS1 and SOCS3 have multiple target proteins (Croker et al., 
2008; Dimitriou et al., 2008). Although we have demonstrated 
that iNOS is a biologically relevant SPSB2 target, it is possible 
that there are others also containing the alNNN sequence (where 
a and l are acidic and aliphatic residues, respectively). More-
over, all four SPSB proteins reportedly interact with the hepato-
cyte growth factor receptor c-Met, and overexpression of SPSB1 
but not other SPSB proteins enhanced hepatocyte growth factor 
signaling. The interaction with c-Met was shown to be direct 
using  purified  recombinant  and  in  vitro  transcribed  proteins 
(Wang et al., 2005), but c-Met does not contain the NNN se-
quence, raising the possibility that yet another interaction site 
exists on the SPRY domain of the SPSB family.
Functional redundancy within the SPSB family may con-
tribute to the modest phenotype observed in SPSB2-deficient 
mice, which have a decreased blood urea level and 25% reduc-
tion in circulating platelets (Masters et al., 2005). The basal 
level of iNOS activity appears to be continuously induced in   
organs such as lung, kidney, and liver (Nathan and Xie, 1994b; 
Ricciardolo  et  al.,  2004),  where  SPSB2  is  the  predominant 
SPSB  protein  (Masters  et  al.,  2005).  Loss  of  SPSB2  in  the 
knockout, coupled with low levels of SPSB1 and SPSB4 in 
these organs might lead to increased iNOS activity and thus in-
creased Arg consumption. As Arg is also converted to urea by 
arginase (Wu and Morris, 1998), a reduction in available Arg 
may well explain the decreased blood urea levels in the SPSB2 
knockout mice.
We observed enhanced NO levels in SPSB2-deficient cells 
after challenge with endotoxin (LPS), gram-positive L. mono­
cytogenes and mycobacteria, and L. major parasites, all of which 
trigger host responses via different Toll-like receptors and sig-
naling pathways to converge on the rapid induction of iNOS 
(Korbel et al., 2008; Liese et al., 2008; Corr and O’Neill, 2009). 
Although mycobacterial infection of BMDMs resulted in en-
hanced NO production in cells lacking SPSB2 (Fig. 6 D), we 
did not observe any significant differences in M. tuberculosis 
(H37Rv) survival in SPSB2-deficient macrophages compared 
Figure 7.  SPSB2-deficient macrophages show enhanced killing of L. major parasites. (A) BMDMs from Spsb2
+/+, Spsb2
/, and Spsb2
T/+ mice were 
incubated in the presence of L. major promastigotes with or without 10 ng/ml IFN- for 48 h. Culture supernatants were then assayed for NO production. 
Data are shown as mean of triplicate cultures ± SD and are representative of four separate experiments. (B and C) BMDMs from Spsb2
+/+ and Spsb2
/ 
mice were infected with L. major promastigotes. The percentage of infected cells was determined at 5 and 48 h after infection. (C) 5 µM of the iNOS inhibi-
tor 1400W was added to cultures 5 h after infection. Data are shown as mean ± SD (n = 3, where each replicate represents cells derived from individual 
mice). *, P < 0.05; **, P < 0.005.JCB • VOLUME 190 • NUMBER 1 • 2010   138
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approval was obtained from the Animal Ethics Committee at the Walter 
and Eliza Hall Institute of Medical Research.
Cytokines and antibodies
LPS from Salmonella minnesota was obtained from Enzo Life Sciences, Inc.   
Murine IFN- was obtained from PeproTech, and murine TNF was obtained 
from  eBioscience.  Rabbit  polyclonal  anti-SPSB2  antibodies  have  been  de-
scribed previously (Masters et al., 2005). Affinity-purified anti-SPSB2 anti-
bodies were either conjugated to N-hydroxysuccinimide (NHS)–Sepharose at 
1.5 mg/ml or biotinylated using sulfo-NHS-biotin (Thermo Fisher Scientific) ac-
cording to the manufacturer’s instructions. Mouse monoclonal anti-iNOS anti-
body was obtained from BD, mouse monoclonal anti–-tubulin antibody 
was obtained from Sigma-Aldrich, and rat anti-Flag antibody was a gift 
from D. Huang and L. O’Reilly (The Walter and Eliza Hall Institute of 
Medical Research).
Preparation of SPSB2 protein
The construct used for expression of recombinant murine SPSB2 SPRY do-
main protein (residues 12–224) has been described previously (Yao et al., 
2005). SPSB2 (12–224) was expressed as a GST fusion protein in BL21 
(DE3) Escherichia coli. For ITC and coprecipitation experiments, bacteria 
were grown in Luria broth. For NMR analysis, bacteria were grown in M9 
minimal media supplemented with 
15N NH4Cl (99%; 1 g/liter). The GST 
fusion protein was purified from clarified cell lysates using glutathione–
Sepharose 4B (GE Healthcare) and then cleaved in situ using thrombin 
(Roche). The cleaved SPSB2 (12–224) protein was then concentrated and fur-
ther purified by gel filtration using a Superdex 200 column (GE Healthcare).
ITC
Wild-type and mutant iNOS N-terminal peptides, corresponding to Lys19-
Thr31 of mouse iNOS, were synthesized by GL Biochem Ltd (Table I). 
These peptides were N-terminally acetylated and C-terminally amidated. 
All ITC measurements were performed at 25°C using an Omega VP-ITC 
(MicroCal Inc.). SPSB2 (12–224) was dialyzed against buffer (100 mM 
Tris-HCl and 150 mM NaCl, pH 8.0), and wild-type and mutant iNOS   
small molecule inhibitors that could disrupt the endogenous 
SPSB–iNOS interaction and thus prolong the intracellular life-
time of iNOS. Providing more of the stimulus systemically can 
often result in widespread toxic effects. One of the advantages 
of disrupting SPSB2-mediated degradation of iNOS is that the 
effects should only be observed in the target cells, specifically 
where and when iNOS is expressed in response to infection. 
Although extending the half-life of iNOS may result in cellular 
toxicity,  this  has  the  potential  to  be  of  particular  benefit  in 
chronic and persistent infections such as tuberculosis or leish-
maniasis. In these diseases, even in individuals who appear   
asymptomatic, the pathogen manages to evade the host defense 
system (Bogdan, 2008), emerging with devastating effect as in-
dividuals age or the immune system is weakened as is the case 
in AIDS patients.
Materials and methods
Mice
Mice with a homozygous deletion of the Spsb2 gene (Spsb2
/) have 
been described previously (Masters et al., 2005) and were maintained on 
a C57BL/6 background. pUBc constructs containing the SPSB2 (Spsb2) 
coding region with (residues 3–265; Spsb2
T/+) and without the SOCS box 
(residues 2–224; Spsb2SB
T/+) were generated to express SPSB2 with an 
N-terminal Flag epitope under the ubiquitin C promoter. Transgenic con-
structs were injected into C57BL/6 blastocysts followed by implantation 
into pseudopregnant C57BL/6 females. Progeny were screened by South-
ern blotting for germline transmission of the transgene. Protein expression 
was confirmed by immunoprecipitation and Western blotting with anti-Flag 
antibodies. All mice were bred in pathogen-free facilities at the Walter and 
Figure 8.  SPSB2 is the adaptor protein in the E3 ubiquitin ligase complex that ubiquitinates iNOS, targeting it for proteasomal degradation. iNOS is 
rapidly induced in response to microbial pathogens and cytokines via the nuclear factor B (NF-B) and STAT1 signaling pathways. iNOS utilizes l-Arg 
to generate NO, a source of potent RNS that play a critical role in the killing of intracellular pathogens. SPSB2 interacts with iNOS via the SPSB2 SPRY 
domain and binds to an elongin BC complex via its SOCS box, recruiting Cullin5 and Rbx2 to form an active E3 ubiquitin ligase that polyubiquitinates 
iNOS, targeting it for proteasomal degradation.139 SPSB2 targets iNOS for proteasomal degradation • Kuang et al.
Real-time quantitative PCR
BMDMs were generated as described in Generation of macrophages and 
replated at 1.0 × 10
6 cells/well on 6-well plates (Costar) in DME contain-
ing 10% FCS and 20% L-cell–conditioned media. The following day, tripli-
cate cultures derived from three independent mice were incubated with   
10 ng/ml murine IFN- and 100 ng/ml LPS. Total cellular RNA was iso-
lated using the RNeasy kit (QIAGEN), and quantitative PCR was performed 
essentially as described previously (Masters et al., 2005) using the Quanti-
Tect SYBR green PCR kit (QIAGEN).
Primer sequences used were as follows: GAPDH (glyceraldehyde 
3-phosphate  dehydrogenase)  forward,  5-TTGTCAAGCTCATTTCCT-
GGT-3; and reverse, 5-TTACTCCTTGGAGGCCATGTA-3; and SPSB2 
forward,  5-AAGAAGAGTGGAGGAACCACAAT-3;  and  reverse,   
5-CAAAGGCAGAGTGGATATTTGAC-3. Relative expression was deter-
mined by normalizing the quantity of the gene of interest to the quan-
tity of GAPDH. Each measurement was performed in duplicate.
Protein production for ubiquitination assays
Mouse Cullin5 was coexpressed as two domains, the N-terminal domain 
(1–384) and C-terminal domain (385–780; Zheng et al., 2002). The   
C-terminal domain of Cullin5 was cloned into the second multiple cloning 
site of pACYC-DUET (EMD), whereas mouse Rbx2 was cloned into the first 
multiple cloning site, resulting in a His6 tag at its N terminus. The N-terminal 
domain of Cullin5 was cloned as a GST fusion protein into pGEX-4T1, 
and the two vectors were coexpressed in BL21 (DE3) cells to yield a ter-
nary  GST-Cul5(N-terminal  domain)/His6-Rbx2/Cul5(C-terminal  domain) 
complex. Expression was performed in Luria broth media at 18°C over-
night after induction using 1 mM isopropyl -d-1-thiogalactopyranoside 
when the OD600 was 0.7. The cells were harvested by centrifugation and 
then lysed using lysozyme and sonication. The complex was bound to   
Ni–nitrilotriacetic  acid  resin,  washed,  and  eluted  in  buffer  containing   
250 mM imidazole. The eluant was then bound to glutathione-Sepharose 
and washed thoroughly in PBS to remove excess Rbx2. The complex was 
then eluted from the resin by thrombin proteolysis of the GST fusion tag 
and purified by size-exclusion chromatography using a Superdex 200 
16/60 column. Finally, the purified E3 ligase was concentrated to 2 mg/ml. 
Murine UbcH5a (E2) was expressed as a GST fusion protein by cloning 
into pGEX-4T and expressed in BL21 (DE3) cells at 37°C for 2 h after iso-
propyl -d-1-thiogalactopyranoside induction. After cell lysis, the protein 
was purified using glutathione-Sepharose and eluted by thrombin diges-
tion. Size-exclusion chromatography using a Superdex 75 16/60 column 
was performed as the final step in purification. Human E1 (GST tagged) 
was purchased from Enzo Life Sciences, Inc. Bovine ubiquitin was pur-
chased from Sigma-Aldrich.
Ubiquitination assays
Cell-free  ubiquitination  reactions  contained  0.1  µM  E1,  2.5  µM  E2,   
2.5 µM E3, 50 µM ubiquitin, and 5 µM SPSB2/elongin BC and were incu-
bated for the indicated time periods at 37°C. Cell lysate was added as 
substrate. Reactions were performed in 20 µl in 20 mM Tris-HCl, 50 mM 
NaCl, 5 mM MgCl2, 2.5 mM ATP, and 0.1 mM DTT and were stopped by 
the addition of 2× SDS-PAGE loading buffer and heating at 95°C for   
5 min. Results were visualized by Western blotting using anti-iNOS mono-
clonal antibody after SDS-PAGE.
NO production
L. monocytogenes strain was maintained by weekly subculture on horse 
blood agar. Cultures were periodically renewed from freeze-dried stock to 
maintain a constant level of virulence (Zhan and Cheers, 1998). BMDMs 
(5 × 10
5 cells per well) were preincubated with or without 20 ng/ml IFN- 
overnight, washed with PBS, and infected with L. monocytogenes at a ratio 
of 100 bacteria per cell in DME without antibiotics for 30 min. Cells were 
then washed with PBS and cultured in DME with 10% FBS containing   
10 µg/ml gentamicin (Sigma-Aldrich) to kill residual or adherent extracel-
lular bacteria. Culture supernatants were assayed for nitrite 16 h after in-
fection. BMDMs were infected with M. bovis BCG at a multiplicity of 3:1 
for 2 h without antibiotics in the absence or presence of 20 ng/ml IFN-, 
and extracellular bacilli were removed by washing. Culture supernatants 
were then assayed for nitrite 24 and 48 h after infection. L. major promas-
tigotes (LRC-L137 V 121) were grown in M199 medium with 10% FBS and 
were in the stationary phase of growth. BMDMs were cultured in a U-bottom 
96-well plate (10
5 cells per well) and preincubated with 10 ng/ml of   
cytokines for 2 h before infection with promastigotes at a ratio of five pro-
mastigotes per cell. Cytokines were maintained throughout. Supernatants 
were assayed for nitrite at 48 h.
N-terminal peptides were prepared in the same buffer from 5-mM stocks. 
Solutions of 5–10 µM SPSB2 (12–224) in the cell were titrated by injection 
of a total of 290 µl of 50–500 µM of iNOS peptides. Data analysis was 
performed using the evaluation software Origin version 5.0 (MicroCal 
Inc.). Parameters were derived from a nonlinear least squares fit to the 
data, using the “one set of sites” model.
NMR spectroscopy
NMR  spectra  were  recorded  on  a  spectrometer  (Avance  500;  Bruker) 
equipped with a TXI cryoprobe. The 
1H chemical shifts were referenced in-
directly to DSS at 0 ppm via the H2O signal, and the 
15N chemical shifts 
were  referenced  indirectly  using  the  absolute  frequency  ratio  (Wishart   
et al., 1995). Spectra were processed using Topspin version 1.3 (Bruker 
BioSpin) and analyzed using XEasy version 1.3 (Bartels et al., 1995). 
An 
15N-labeled SPSB2 (12224) sample for NMR analysis was prepared 
in H2O containing 5% 
2H2O, 10 mM Na phosphate, 50 mM Na chloride,   
2 mM EDTA, 2 mM DTT, and 0.02% (wt/vol) Na azide at pH 7.0. A two-
dimensional 
1H-
15N  HSQC  spectrum  of  0.1  mM 
15N-labeled  SPSB2 
(12224) was recorded at 22°C using a data matrix size of 2,048 × 256 
and with 128 scans per t1 increment. The spectral widths were 13.5 ppm 
for 
1H and 40.0 ppm for 
15N; carrier frequencies were 4.7 ppm for 
1H and 
118 ppm for 
15N. Unlabeled iNOS N-terminal peptide (wild type) was 
then titrated into the 
15N-labeled SPSB2 (12224) sample, and 
1H-
15N 
HSQC spectra were recorded at 
15N-labeled SPSB2/iNOS peptide ratios 
of 1:0.5, 1:1, and 1:1.5.
Generation of macrophages
Murine BMDMs were derived by culture of whole bone marrow in DME sup-
plemented  with  100  U/ml  penicillin,  0.1  mg/ml  streptomycin,  10%  FBS 
(Sigma-Aldrich), and 20% L-cell–conditioned medium as a source of macro-
phage colony-stimulating factor (Wormald et al., 2006) and maintained at 
37°C in a humidified atmosphere with 10% CO2. FACS analysis confirmed 
that >95% of adherent cells were positive for CD11b expression (Mac-1) after 
6 d in culture. To elicit macrophages, mice were given an intraperitoneal injec-
tion with 1 ml of aged 3% Brewer thioglycollate medium (Difco) and sacrificed 
after 3 d; peritoneal cells were then harvested by lavage of the peritoneal cav-
ity with PBS. Before stimulation, peritoneal cells were cultured overnight in 
DME supplemented with 100 U/ml penicillin, 0.1 mg/ml streptomycin, 10% 
FBS, and 20% L-cell–conditioned medium. FACS analysis confirmed that ad-
herent cells were >98% positive for CD11b (Mac-1).
cDNA constructs and transient transfection of 293T cells
pEFBOS constructs encoding murine SPSB proteins with an N-terminal Flag 
epitope tag were generated by PCR to give fragments with in-frame AscI 
and MluI restriction enzyme sites at the N and C termini, respectively, and 
subcloned into the mammalian expression vector pEF-Flag-I, a derivative of 
pEFBOS. SPSB point mutants were generated using the PCR-based tech-
nique, splicing by overlap extension (Masters et al., 2006; Kuang et al., 
2009). 293T cells (DuBridge et al., 1987) were maintained in DME sup-
plemented with 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 10% 
FBS. Cells were transiently transfected using FuGene6 Reagent (Roche) ac-
cording to the manufacturer’s instructions.
Immunoprecipitation and Western blotting
In coprecipitation experiments, bacterially expressed SPSB2 (12–224) and 
SPSB2 protein in which Tyr120 had been mutated to Ala (Y120A-SPSB2; 
12–224) were conjugated to NHS-activated Sepharose (GE Healthcare) 
according  to  the  manufacturer’s  instructions.  iNOS  expressing  BMDM   
lysates were precleared with Sepharose beads alone for 1 h and then in-
cubated with SPSB2-coupled Sepharose for 3 h at 4°C. iNOS interaction 
was then detected by SDS-PAGE and Western blotting.
For immunoprecipitation experiments, BMDMs and peritoneal macro-
phages were incubated with IFN- and LPS overnight and lysed in kinase 
assay lysis buffer (Nicholson et al., 1995) containing protease inhibitors 
(Complete Cocktail tablets; Roche), 1 mM phenylmethylsulfonyl fluoride,   
1 mM Na3VO4, and 1 mM NaF. Proteins were immunoprecipitated using 
anti-Flag antibody conjugated to Sepharose (M2; Kodak). Proteins were 
separated by SDS-PAGE under reducing conditions and electrophoretically 
transferred  to  BioTrace  polyvinylidene  fluoride  membranes  (Millipore). 
Membranes were blocked overnight in 10% wt/vol skim milk and incu-
bated with primary antibody for 2 h. Antibody binding was visualized with 
either peroxidase-conjugated sheep anti–mouse Ig antibody (GE Health-
care) or peroxidase-conjugated sheep anti–rabbit Ig antibody (Millipore) 
and the ECL system (GE Healthcare). To reblot, the membrane was first 
stripped of antibodies in 0.1 M Gly, pH 2.9.JCB • VOLUME 190 • NUMBER 1 • 2010   140
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NO production by macrophages in response to LPS, L. monocyto-
genes, M. bovis BCG, or L. major was determined by measuring nitrite 
(NO2
), a stable and nonvolatile breakdown product of NO, in culture   
supernatants using the Griess reaction (Stuehr and Nathan, 1989). 100 µl 
of culture supernatants was mixed with 10 µl of 1% sulphanilamide, incu-
bated at room temperature for 10 min, and then mixed with 10 µl of 0.1% 
N-1-naphthylethylenediamine  dihydrochloride  in  2.5%  polyphosphoric 
acid and further incubated at room temperature for 5 min. Absorbance 
was measured at 550 nm, and nitrite concentration was determined by 
comparison with Na nitrite standards. The statistical significance of data 
was determined using the Student’s t test.
In vitro killing of L. major parasites
BMDMs were plated onto glass coverslips at a density of 5 × 10
4 macro-
phages per well in 0.5 ml DME with 10% FBS and 20% L-cell–conditioned 
medium and allowed to adhere for 3 d. Nonadherent cells were removed 
by washing, and adherent cells were infected with L. major promastigotes 
at a ratio of 10 parasites per cell for 4 h. Free parasites were removed by 
vigorous washing, and cells were incubated for a further 48 h. 5 µM of 
iNOS inhibitor 1400W (Garvey et al., 1997) was added to cultures at   
5 h after infection. The cells were fixed and stained with Giemsa, and 
the percentage of macrophages infected with parasites was determined 
for each time point with at least 300 cells counted per sample (Scott   
et al., 2000).
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LPS stimulus in SPSB2-deficient macrophages. Fig. S4 shows that iNOS pep-
tide can inhibit iNOS ubiquitination. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.200912087/DC1.
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